DaVita Inc. reported results for the quarter ended 2026 with revenue of $3.55B, net income of $265.4M and diluted EPS of $4.02, versus $3.38B, $199.34M and $2.58, respectively, in the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$3.55B$3.38B5.2% | Net income²$265.4M$199.34M33.1% | Diluted EPS³$4.02$2.5855.8% |
¹ Reported as “Total revenues”. ² Reported as “Net income attributable to DaVita Inc.”. ³ Reported as “Diluted earnings per share attributable to DaVita Inc.”.
Business Highlights
- Revenue growth of roughly 5.6% year-to-date was driven by higher U.S. dialysis volumes and a 17% increase in ancillary revenue.
- Commercial payor mix pressure continued to affect revenue per treatment, partly offset by Medicare base rate increases.
- Integrated Kidney Care (IKC) expanded to about 64.9k patients in risk-based arrangements, with plans to broaden expanded hemodialysis access network-wide.
- Operationally, treatment volumes rose in Q2 versus Q1, with productivity gains, reduced mortality impact and international center growth to 595 centers.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.